Functions of the MDM2 oncoprotein
暂无分享,去创建一个
A. Levine | D. Freedman | L. Wu | D. A. Freedman | L. Wu | A. J. Levine | L. Wu | L. Wu
[1] M. Ladanyi,et al. MDM2 gene amplification in metastatic osteosarcoma. , 1993, Cancer research.
[2] A. Bernheim,et al. MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). , 1996, Cytogenetics and cell genetics.
[3] R. Tjian,et al. Repression of p53-mediated transcription by MDM2: a dual mechanism. , 1997, Genes & development.
[4] M. Oren,et al. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. , 1995, Nucleic acids research.
[5] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[6] A. Levine,et al. Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6 , 1998, Molecular and Cellular Biology.
[7] A. Levine,et al. Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.
[8] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[9] A. Levine,et al. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein , 1996, Molecular and cellular biology.
[10] V. Reinke,et al. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo , 1997, Oncogene.
[11] Y. Yoshihama,et al. p53 and MDM2 expression in oral squamous cell carcinoma. , 1996, Oncology.
[12] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[13] T. Kinoshita,et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. , 1994, Blood.
[14] A. Levine,et al. Molecular Abnormalities of mdm 2 and p 53 Genes in Adult Soft Tissue Sarcomas ' , 2022 .
[15] A. Levine,et al. Induced α Helix in the VP16 Activation Domain upon Binding to a Human TAF , 1997 .
[16] A. Levine,et al. The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro , 1997, Molecular and cellular biology.
[17] Hirofumi Tanaka,et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.
[18] A. Levine,et al. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.
[19] S. Stass,et al. The human MDM-2 oncogene is overexpressed in leukemias. , 1993, Blood.
[20] M. Schwab,et al. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. , 1995, Oncogene.
[21] P. Meltzer,et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. , 1993, Cancer research.
[22] B. Vogelstein,et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.
[23] A. Levine,et al. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. , 1993, Oncogene.
[24] Yoichi Taya,et al. DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.
[25] W. Maltzman,et al. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.
[26] A. Levine,et al. Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis , 1997, Oncogene.
[27] M. Raffeld,et al. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. , 1996, The American journal of pathology.
[28] W. Sellers,et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2 , 1995, Nature.
[29] A. Jochemsen,et al. MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.
[30] G. Lozano,et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. , 1997, Genes & development.
[31] Lawrence A. Donehower,et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.
[32] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[33] V. P. Collins,et al. Analysis of glioma cell lines for amplification and overexpression of MDM2 , 1994, Genes, chromosomes & cancer.
[34] G. Lozano,et al. The organization and expression of the mdm2 gene. , 1996, Genomics.
[35] M. Oren,et al. mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.
[36] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[37] A. Levine,et al. Differential Regulation of the p21/WAF-1 and mdm2 Genes after High-Dose UV Irradiation: p53-Dependent and p53-Independent Regulation of the mdm2 Gene , 1997, Molecular medicine.
[38] G. Reifenberger,et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.
[39] S. Tapscott,et al. Amplification of MDM2 inhibits MyoD-mediated myogenesis , 1996, Molecular and cellular biology.
[40] A. Levine,et al. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[41] P S Meltzer,et al. Isolation of genes amplified in human cancers by microdissection mediated cDNA capture. , 1996, Human molecular genetics.
[42] H. Nguyen,et al. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[44] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[45] A. Levine,et al. The MDM2 Oncoprotein Binds Specifically to RNA through its RING Finger Domain , 1996, Molecular medicine.
[46] P. Meltzer,et al. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. , 1996, Cancer research.
[47] Bert Vogelstein,et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.
[48] M. Ladanyi,et al. p53 and MDM2 alterations in osteosarcomas , 1997, Cancer.
[49] A. Levine,et al. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes , 1994, Molecular and cellular biology.
[50] Jiandong Chen,et al. Synergistic activation of p 53 by inhibition of MDM 2 expression and DNA damage , 1997 .
[51] A. Levine,et al. The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.
[52] A. Levine,et al. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[53] Yolande F M Ramos,et al. Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. , 1997, Genomics.
[54] C. Poremba,et al. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. , 1995, Oncology research.
[55] P. Freemont,et al. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. , 1994, Trends in biochemical sciences.
[56] G. Cooper,et al. Identification of the MDM2 Oncoprotein as a Substrate for CPP32-like Apoptotic Proteases* , 1997, The Journal of Biological Chemistry.
[57] M. Oren,et al. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. , 1994, Genes & development.
[58] R. Tjian,et al. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.
[59] A. Levine,et al. Proteolytic Cleavage of the mdm2 Oncoprotein during Apoptosis* , 1997, The Journal of Biological Chemistry.
[60] M. Oren,et al. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. , 1993, Oncogene.
[61] B. Vogelstein,et al. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[62] D. Beach,et al. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. , 1994, The EMBO journal.
[63] A. Levine,et al. Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene , 1995, Molecular medicine.
[64] A. J. Levine. The p53 tumor-suppressor gene. , 1992, The New England journal of medicine.
[65] Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. , 1998, The EMBO journal.
[66] U. Francke,et al. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line , 1987, Somatic cell and molecular genetics.
[67] Guillermina Lozano,et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.
[68] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[69] J. Landers,et al. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. , 1994, Oncogene.
[70] D. George,et al. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.
[71] A. Levine,et al. A Genetic Approach to Mapping the p53 Binding Site in the MDM2 Protein , 1997, Molecular medicine.
[72] J. Blaydes,et al. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2 , 1997, Oncogene.
[73] C. Finlay,et al. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth , 1993, Molecular and cellular biology.
[74] Jiandong Chen,et al. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[75] M. Sheikh,et al. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. , 1993, Cancer research.